Adma Biologics (ADMA) Cash from Financing Activities (2011 - 2025)
Adma Biologics (ADMA) posted Cash from Financing Activities of -$9.1 million for Q4 2025, up 67.23% on a QoQ basis from -$27.8 million in Q3 2025, and up 70.61% year-over-year from -$5.3 million in Q4 2024.
Adma Biologics (ADMA) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Adma Biologics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$9.1 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 70.61% year-over-year to -$9.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$44.0 million (up 24.49% YoY) and the FY2025 annual result came in at -$44.0 million, up 24.49% from the prior year.
- Cash from Financing Activities was -$9.1 million for Q4 2025 at Adma Biologics, up from -$27.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $62.7 million in Q4 2022 and bottomed at -$39.0 million in Q4 2023.
- A 5-year average of $4.4 million and a median of -$340520.5 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities jumped 1014330.22% — and 2024, when it plunged 6221.88%.
- Adma Biologics' Cash from Financing Activities stood at $53.8 million in 2021, then climbed by 16.58% to $62.7 million in 2022, then slumped by 162.15% to -$39.0 million in 2023, then increased by 20.44% to -$31.0 million in 2024, then surged by 70.61% to -$9.1 million in 2025.
- Business Quant data shows ADMA's Cash from Financing Activities at -$9.1 million in Q4 2025, -$27.8 million in Q3 2025, and $48000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | -9.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.12 Mn |
| Dec 31, 2025 | -9.12 Mn |
| Sep 30, 2025 | -27.83 Mn |
| Sep 30, 2025 | -27.83 Mn |
| Jun 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | -7.13 Mn |
| Mar 31, 2025 | -7.13 Mn |
| Dec 31, 2024 | -31.03 Mn |
| Dec 31, 2024 | -31.03 Mn |
| Sep 30, 2024 | -25.47 Mn |
| Sep 30, 2024 | -25.47 Mn |
| Jun 30, 2024 | -362,000.00 |
| Jun 30, 2024 | -362,000.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -39.00 Mn |
| Dec 31, 2023 | -39.00 Mn |
| Sep 30, 2023 | 416,000.00 |
| Sep 30, 2023 | 416,000.00 |